Interventions and outcomes of multiple myeloma patients receiving salvage treatment after BCMA-directed CAR T therapy

Researchers analyzed salvage treatments and outcomes of 79 patients with multiple myeloma who had disease progression after BCMA-directed CAR T-cell therapy. Patients were from two academic institutions and had a median of two (range, 1-10) lines of therapy. For patients who received a CAR T-cell therapy as salvage therapy, overall survival had not been reached at the median follow-up of 21.3 months.